Biovica – our doubling candidate is reporting tomorrow
I have been long Biovica (BIOVIC) for some time. The thesis has been delayed by the FDA approval delay due to FDA Covid congestion. Many retail investors lost patience. The stock is down, but the thesis is unchanged. One or two months delay should not affect the value of the company. FDA Covid-caused FDA congestion … Continue reading Biovica – our doubling candidate is reporting tomorrow
Copy and paste this URL into your WordPress site to embed
Copy and paste this code into your site to embed